ACADIA Pharmaceuticals (MEX:ACAD) Current Deferred Taxes Liabilities: MXN0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:ACAD ACADIA Pharmaceuticals Inc MEX:ACAD
71 GF Score
Price MXN453.75
GF Value MXN353.86
Valuation Modestly Overvalued
! 10 Warning Signs
View Full Analysis

What is ACADIA Pharmaceuticals Current Deferred Taxes Liabilities?

ACADIA Pharmaceuticals MEX:ACAD 71 Current Deferred Taxes Liabilities is MXN0 Mil as of Jun. 2026. GuruFocus rates MEX:ACAD with a GF Score™ of 71/100 and a GF Value™ of MXN353.86 (Modestly Overvalued). The stock has 10 warning signs investors should review.

Current Deferred Taxes Liabilities represent future tax liabilities, resulting from temporary differences between book (accounting) value of assets and liabilities and their tax value, or timing differences between the recognition of gains and losses in financial statements and their recognition in a tax computation. Deferred tax liabilities generally arise where tax relief is provided in advance of an accounting expense, or income is accrued but not taxed until received.

ACADIA Pharmaceuticals's current deferred tax liabilities for the quarter that ended in Jun. 2026 was MXN0 Mil.

ACADIA Pharmaceuticals Current Deferred Taxes Liabilities Related Terms

ACADIA Pharmaceuticals Current Deferred Taxes Liabilities Historical Data

* Premium members only.

The historical data trend for ACADIA Pharmaceuticals's Current Deferred Taxes Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ACADIA Pharmaceuticals Current Deferred Taxes Liabilities Chart

ACADIA Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Deferred Taxes Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

ACADIA Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Current Deferred Taxes Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
MEX:ACAD
71GF Score
ACADIA Pharmaceuticals Inc MEX:ACAD
Current Deferred Taxes Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Taxes Liabilities of MXN0 Mil mean?
ACADIA Pharmaceuticals (MEX:ACAD) has a Current Deferred Taxes Liabilities of MXN0 Mil as of Jun. 2026. Current Deferred Tax Liabilities records the total amount of taxes due for the period but not yet paid. View historical data on ACADIA Pharmaceuticals and its competitors.
Is ACADIA Pharmaceuticals' Current Deferred Taxes Liabilities too high?
ACADIA Pharmaceuticals' current Current Deferred Taxes Liabilities is MXN0 Mil. Overall, ACADIA Pharmaceuticals has a GF Score™ of 71/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does ACADIA Pharmaceuticals' Current Deferred Taxes Liabilities compare to LEGN and TNGX?
ACADIA Pharmaceuticals' Current Deferred Taxes Liabilities of MXN0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Taxes Liabilities for a Biotechnology company?
A good Current Deferred Taxes Liabilities depends on the Biotechnology industry context. However, Current Deferred Taxes Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Taxes Liabilities mean?
A high Current Deferred Taxes Liabilities can signal that a stock is expensive relative to its fundamentals. Current Deferred Tax Liabilities records the total amount of taxes due for the period but not yet paid. View historical data on ACADIA Pharmaceuticals and its competitors. ACADIA Pharmaceuticals's current Current Deferred Taxes Liabilities is MXN0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ACADIA Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, ACADIA Pharmaceuticals (MEX:ACAD) is currently considered Modestly Overvalued. The stock's GF Value™ is MXN353.86, compared to a current price of MXN453.75 — trading 28.2% above its estimated fair value. The current Current Deferred Taxes Liabilities is MXN0 Mil. ACADIA Pharmaceuticals' overall GF Score™ is 71/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Taxes Liabilities calculated?
Current Deferred Taxes Liabilities is calculated from a company's financial statements. For ACADIA Pharmaceuticals (MEX:ACAD), the current Current Deferred Taxes Liabilities is MXN0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ACADIA Pharmaceuticals (MEX:ACAD) Overvalued in 2026?

Based on GuruFocus' analysis, ACADIA Pharmaceuticals stock appears to be overvalued. The current stock price of MXN453.75 is trading 28.2% above its estimated GF Value™ of MXN353.86. GuruFocus considers ACADIA Pharmaceuticals to be Modestly Overvalued.

Key valuation signals for MEX:ACAD:

  • Current Deferred Taxes Liabilities: MXN0 Mil
  • GF Value™: MXN353.86 vs. price of MXN453.75 (28.2% above fair value)
  • GF Score™: 71/100 with 10 warning signs

No single metric tells the full story. See the MEX:ACAD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ACADIA Pharmaceuticals Business Description

Other Exchanges ACAD:USADR6:Germany
Address 12830 El Camino Real, Suite 400, San Diego, CA, USA, 92130
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-211, ACP-711, ACP-2591, etc.
71GF Score

Get the complete analysis for MEX:ACAD

Current Deferred Taxes Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN453.75
Price
MXN353.86
GF Value